Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 2,501–2,600 of 15,747
Sönmezer, M. Ç., Şahin, T. K., Erul, E., Ceylan, F., Hamurcu, M. Y., Morova, N., Al, I. R., & Ünal, S. (2022) · Vaccines · doi:10.3390/vaccines10020278 · Cited by 49
“1% for the mRNA-1273 (Moderna, Cambridge, MA, USA) vaccine [7], and an efficacy of 95% for the BNT162b2 (Pfizer–BioNTech, Manhattan, NY, USA) vaccine [8].”
BackgroundSelf-citationKelp, N., Witt, J. K., & Sivakumar, G. (2021) · Science Communication · doi:10.1177/10755470211063628 · Cited by 47
“There is a range of possible outcomes with various likelihoods that can occur following COVID vaccination (Polack et al., 2020).”
BackgroundMessenger RNA vaccines against SARS-CoV-2
Topol, E. J. (2021) · Cell · doi:10.1016/j.cell.2020.12.039 · Cited by 42
Review of the COVID-19 Risk in Multiple Sclerosis
Chaudhry, F., Jageka, C., Levy, P. D., Cerghet, M., & Lisak, R. P. (2021) · Journal of Cellular Immunology · doi:10.33696/immunology.3.080 · Cited by 44
Vaccine escape in a heterogeneous population: insights for SARS-CoV-2 from a simple model
Gog, J. R., Hill, E. M., Danon, L., & Thompson, R. N. (2021) · Royal Society Open Science · doi:10.1098/rsos.210530 · Cited by 54
Projecting the impact of a two-dose COVID-19 vaccination campaign in Ontario, Canada
VILCHES, T. N., Zhang, K., Exan, R. V., Langley, J. M., & Moghadas, S. M. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.03.058 · Cited by 48
Comparing reactogenicity of COVID-19 vaccines: a systematic review and meta-analysis
Sutton, N., Ramos, A. S. F., Beales, E. R., Smith, D., Ikram, S., Galiza, E. P., Hsia, Y., & Heath, P. T. (2022) · Expert Review of Vaccines · doi:10.1080/14760584.2022.2098719 · Cited by 46
Guidara, C. L., Adamo, R., Sala, C., & Micoli, F. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25105487 · Cited by 57
“RNA: RNA-based vaccines exploit the host cell translational machinery to produce the selected antigens and proved to be game changers to fight COVID-19 [91,92].”
BackgroundLipid Nanoparticle-Based Delivery SystemA Competing Place for mRNA Vaccines
Zhang, X., Li, Y., & Zhou, Z. (2024) · ACS Omega · doi:10.1021/acsomega.3c08353 · Cited by 45
Follmann, D. A., O’Brien, M. P., Fintzi, J., Fay, M. P., Montefiori, D. C., Mateja, A., Herman, G. A., Hooper, A. T., Turner, K. C., Chan, K.-C., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39292-w · Cited by 41
Manzo, C., Natale, M., & Castagna, A. (2021) · Aging Medicine · doi:10.1002/agm2.12171 · Cited by 43
Wang, X., Mahmood, S. F., Jin, F., Cheah, W. K., Ahmad, M., Sohail, M. A., Ahmad, W., Suppan, V. K. L., Sayeed, M. A., Luxmi, S., et al. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2088406 · Cited by 44
SARS‐CoV‐2 vaccination in solid‐organ transplant recipients: What the clinician needs to know
Giannella, M., Pierrotti, L. C., Helanterä, I., & Manuel, O. (2021) · Transplant International · doi:10.1111/tri.14029 · Cited by 43
“have been extremely effective compared with placebo, reaching efficacy of 94–95% with the mRNA vaccines for protection of COVID-19 [6,7].”
BackgroundPrasad, A., Hurlburt, G. A., Podury, S., Tandon, M., Kingree, S., & Sriwastava, S. (2021) · Neurology International · doi:10.3390/neurolint13030040 · Cited by 46
Kappelman, M. D., Weaver, K. N., Zhang, X., Dai, X., Watkins, R. D., Adler, J., Dubinsky, M. C., Kastl, A., Bousvaros, A., Strople, J. A., et al. (2021) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001619 · Cited by 44
“Based on growing evidence, the US FDA recently announced an EUA to provide a third dose of SARS-CoV-2 mRNA vaccine for moderately to severely immunosuppressed persons, which includes many patients with IBD (12).”
BackgroundInfluentialBurn, E., Li, X., Kostka, K., Stewart, H. M., Reich, C., Seager, S., Duarte‐Salles, T., Fernandez‐Bertolin, S., Aragón, M., Reyes, C., et al. (2022) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.5419 · Cited by 43
Jung, O., Jung, H., Thủy, L. T. T., Choi, M., Kim, S., Jeon, H., Yang, J., Kim, S., Kim, T., Lee, E., et al. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202303857 · Cited by 48
Recommendations for the use of COVID-19 vaccines in patients with immune-mediated kidney diseases
Kronbichler, A., Anders, H., Juarez, G. M. F., Floege, J., Goumenos, D. S., Segelmark, M., Tesař, V., Türkmen, K., van Kooten, C., & Bruchfeld, A. N. (2021) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfab064 · Cited by 50
Saita, M., Yan, Y., Ito, K., Sasano, H., Seyama, K., & Naito, T. (2021) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2021.09.009 · Cited by 42
Lutrick, K., Rivers, P. S., Yoo, Y. M., Grant, L., Hollister, J., Jovel, K. S., Khan, S. R., Lowe, A. A., Baccam, Z., Hanson, H., et al. (2021) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm705152a2 · Cited by 40
Liposome-Based Carriers for CRISPR Genome Editing
Yin, X., Harmancey, R., McPherson, D. D., Kim, H., & Huang, S. L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241612844 · Cited by 46
SARS-CoV-2 Vaccines in Patients With Multiple Myeloma
Gavriatopoulou, M., Ntanasis‐Stathopoulos, I., Korompoki, E., Terpos, E., & Dimopoulos, M. A. (2021) · HemaSphere · doi:10.1097/hs9.0000000000000547 · Cited by 45
Manzia, T. M., Gazia, C., Lenci, I., et al. (2021) · American Journal of Transplantation · doi:10.1111/ajt.16548 · Cited by 43
Individual costs and societal benefits of interventions during the COVID-19 pandemic
Traulsen, A., Levin, S. A., & Saad-Roy, C. M. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2303546120 · Cited by 55
Blood Pressure Increase following COVID-19 Vaccination: A Systematic Overview and Meta-Analysis
Angeli, F., Reboldi, G., Trapasso, M., Santilli, G., Zappa, M., & Verdecchia, P. (2022) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd9050150 · Cited by 51
Vignier, N., Bérot, V., Bonnave, N., Peugny, S., Ballet, M., Jacoud, E., Michaud, C., Gaillet, M., Djossou, F., Blanchet, D., et al. (2021) · Emerging infectious diseases · doi:10.3201/eid2710.211427 · Cited by 46
New-onset IgA nephropathy following COVID-19 vaccination
Ma, Y., & Xu, G. (2022) · QJM · doi:10.1093/qjmed/hcac185 · Cited by 46
Brook, B., Duval, V., Barman, S., Speciner, L., Sweitzer, C., Khanmohammed, A., Menon, M., Foster, K., Ghosh, P., Abedi, K., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adm8451 · Cited by 52
Alwani, S., Wasan, E. K., & Badea, I. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c00128 · Cited by 49
(2021) · doi:10.1101/2021.05.11.21256917 · Cited by 43
“While immunosenescence may reduce the level of antibody responses to immunizations,(20) recent studies on COVID-19 mRNA vaccines have not shown differences in clinical outcomes for the older population.(6) In our study, IMID patients on methotrexate were generally older which may potentially explain some differences i…”
BackgroundSi, R., Yao, Y., Zhang, X., Lu, Q., & Aziz, N. (2021) · Frontiers in Public Health · doi:10.3389/fpubh.2021.702699 · Cited by 53
SARS-CoV-2 convalescence and hybrid immunity elicits mucosal immune responses
Puhach, O., Bellon, M., Adea, K., Bekliz, M., Hosszu-Fellous, K., Sattonnet‐Roche, P., Coudurier-Boeuf, S., Arm‐Vernez, I., Kaiser, L., Eckerle, I., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104893 · Cited by 41
Antibiotic resistance during and beyond COVID-19
Livermore, D. M. (2021) · JAC-Antimicrobial Resistance · doi:10.1093/jacamr/dlab052 · Cited by 51
Gayed, J., Diya, O., Lowry, F. S., Xu, X., Bangad, V., Mensa, F., Zou, J., Xie, X., Hu, Y., Lu, C., et al. (2024) · Vaccines · doi:10.3390/vaccines12020118 · Cited by 44
“…vaccine-experienced individuals ≥ 12 years of age had a safety and tolerability profile similar to that seen with original and the BA.5/BA.5-adapted and BA.1-adapted BNT162b2 vaccines [28–31] and induced substantial increases in neutralizing responses against Omicron XBB.1.5, EG.5.1, and BA.2.86.”
ResultInfluentialSelf-citationOvervad, M., Koch, A., Jespersen, B., Gustafsson, F., Krause, T. G., Hansen, C. H., Ethelberg, S., & Obel, N. (2022) · American Journal of Transplantation · doi:10.1111/ajt.17142 · Cited by 46
RNA Therapeutics: the Next Generation of Drugs for Cardiovascular Diseases
Bejar, N., Tat, T. T., & Kiss, D. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01007-9 · Cited by 46
Peptide-Based Complex Coacervates Stabilized by Cation−π Interactions for Cell Engineering
Sun, Y., Wu, X. J., Li, J., Verma, C. S., Yu, J., & Miserez, A. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.4c14469 · Cited by 56
Tomalka, J. A., Suthar, M. S., Deeks, S. G., & Sékaly, R. (2022) · Nature Immunology · doi:10.1038/s41590-022-01130-4 · Cited by 47
Shmueli, E., Itay, A., Margalit, O., Berger, R., Halperin, S., Jurkowicz, M., Levin, E. G., Levy, I., Olmer, L., Regev‐Yochay, G., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.08.007 · Cited by 47
“The current efficacy data for COVID-19 mRNA vaccines are >90% with a favourable safety profile as demonstrated in pivotal trials [12, 13].”
BackgroundThe potential of RNA-based therapy for kidney diseases
Bondue, T., van den Heuvel, L. P., Levtchenko, E. N., & Brock, R. E. (2022) · Pediatric Nephrology · doi:10.1007/s00467-021-05352-w · Cited by 53
Prophylactic vaccine delivery systems against epidemic infectious diseases
Pan, C., Yue, H., Zhu, L., Ma, G., & Wang, H. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113867 · Cited by 47
“Tozinameran(BNT162b2) Pfizer & BioNTech Liposome 2020 mRNA vaccine [254]”
Alcendor, D. J., Juárez, P. D., Matthews-Juarez, P., Simon, S., Nash, C., Lewis, K., & Smoot, D. T. (2022) · Vaccines · doi:10.3390/vaccines10020211 · Cited by 42
Jia, X., Liu, Y., Wagner, A. M., Chen, M., Zhao, Y., Smith, K. J., Some, D., Abend, A. M., & Pennington, J. P. (2021) · Journal of Chromatography B · doi:10.1016/j.jchromb.2021.123015 · Cited by 46
Angyal, A., Longet, S., Moore, S. C., Payne, R. P., Harding, A. C., Tipton, T., Rongkard, P., Ali, M., Hering, L. M., Meardon, N., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3812375 · Cited by 42
Rapid escape of new SARS-CoV-2 Omicron variants from BA.2-directed antibody responses
Dijokaite-Guraliuc, A., Das, R., Zhou, D., Ginn, H. M., Liu, C., Duyvesteyn, H. M. E., Huo, J., Nutalai, R., Supasa, P., Selvaraj, M., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112271 · Cited by 46
Davidov, Y., Indenbaum, V., Tsaraf, K., Cohen‐Ezra, O., Likhter, M., Yakov, G. B., Halperin, R., Levy, I., Mor, O., Agmon‐Levin, N., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.03.042 · Cited by 44
Ward, H., Cooke, G., Whitaker, M. D., Redd, R., Eales, O. D., Brown, J. C., Collet, K., Cooper, E., Daunt, A., Jones, K., et al. (2021) · medRxiv · doi:10.1101/2021.02.26.21252512 · Cited by 54
Ligand-mediated delivery of RNAi-based therapeutics for the treatment of oncological diseases
Abdelaal, A. M., & Kasinski, A. L. (2021) · NAR Cancer · doi:10.1093/narcan/zcab030 · Cited by 48
“The success of GalNac conjugates is helping to pave the way and the recent use of RNA-based vaccines for protecting individuals from SARS-Cov2 suggests that an exponential increase in RNA therapeutics is on the horizon (159,160).”
BackgroundWebber, T. B., Provinciali, N., Musso, M., Ugolini, M., Boitano, M., Clavarezza, M., D'Amico, M., Defferrari, C., Gozza, A., Briata, I., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.09.030 · Cited by 38
“The immunogenicity of cancer patients is also lower than the general population after contracting SARS-CoV-2 infection [4e6], so that the ability to develop a response to the vaccine was also expected to be different in cancer patients compared to healthy subjects, who attained a 95% efficacy with BNT162b2 vaccine [3].”
BackgroundInfluentialChen, Z., Yang, Y., Qiu, X., Zhou, H., Wang, R., & Xiong, H. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.4c14500 · Cited by 48
Lang, R., Humes, E., Coburn, S. B., Horberg, M. A., Fathi, L., Watson, E. S., Jefferson, C. R., Park, L. S., Gordon, K. S., Akgün, K. M., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.36397 · Cited by 47
A review on nanoparticles categorization, characterization and applications in drug delivery systems
Wani, S. U. D., Ali, M., Masoodi, M. H., Khan, N. A., Zargar, M. I., Mir, R. H., Mir, S. A., Gautam, S. P., Gangadharappa, H. V., & Osmani, R. A. M. (2022) · Vibrational Spectroscopy · doi:10.1016/j.vibspec.2022.103407 · Cited by 66
Neurological Complications Following COVID-19 Vaccination
Chatterjee, A., & Chakravarty, A. (2022) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-022-01247-x · Cited by 52
Pawlowski, C., Rincón-Hekking, J., Awasthi, S., Pandey, V., Lenehan, P. J., Venkatakrishnan, A., Bade, S., O’Horo, J. C., Virk, A., Swift, M. D., et al. (2021) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2021.105923 · Cited by 42
Verger, P., & Peretti‐Watel, P. (2021) · The Lancet Public Health · doi:10.1016/s2468-2667(21)00029-3 · Cited by 44
Pharmacological Treatment of Secondary Lymphedema
Brown, S., Dayan, J. H., Coriddi, M. R., Campbell, A.-C., Kuonqui, K. G., Shin, J., Park, H. J., Mehrara, B. J., & Kataru, R. P. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.828513 · Cited by 47
Pellini, R., Venuti, A., Pimpinelli, F., Abril, E., Blandino, G., Campo, F., Conti, L., VIRGILIO, A. D., Marco, F. D., Domenico, E. G. D., et al. (2021) · Vaccines · doi:10.3390/vaccines9070685 · Cited by 47
“Although data on the safety and efficacy of the BNT162b2 vaccine demonstrate its effectiveness, immunogenicity data are reported only on small cohorts [9], and a phase 2/3 study on vaccine immunogenicity is ongoing [4].”
BackgroundResultCorbett, K. S., Nason, M. C., Flach, B., Gagne, M., O’ Connell, S., Johnston, T. S., Shah, S. N., Edara, V. V., Floyd, K., Lai, L., et al. (2021) · doi:10.1101/2021.04.20.440647 · Cited by 43
“Two mRNA-based vaccines, Moderna’s mRNA58 1273 and Pfizer/BioNTech’s BNT 162b2, both of which encode the prefusion-stabilized spike 59 glycoprotein (S-2P) (2, 3), showed >94% efficacy against symptomatic COVID-19 in interim 60 Phase 3 analyses (4, 5) and are currently being administered globally.”
BackgroundGat, I., Kedem, A., Dviri, M., Umanski, A., Levi, M., Hourvitz, A., & Baum, M. (2022) · Andrology · doi:10.1111/andr.13209 · Cited by 53
Hyperglycemic Emergencies Associated With COVID-19 Vaccination: A Case Series and Discussion
Lee, H. J., Sajan, A., & Tomer, Y. (2021) · Journal of the Endocrine Society · doi:10.1210/jendso/bvab141 · Cited by 44
Gardner, B. J., & Kilpatrick, A. M. (2024) · Viruses · doi:10.3390/v16030479 · Cited by 49
Epigenetic targeting of the ACE2 and NRP1 viral receptors limits SARS-CoV-2 infectivity
Sáiz, M. L., DeDiego, M. L., López-García, D., Corte-Iglesias, V., Raneros, A. B., Astola, I., Asensi, V., López‐Larrea, C., & Suárez-Álvarez, B. (2021) · Clinical Epigenetics · doi:10.1186/s13148-021-01168-5 · Cited by 41
Tomkins‐Netzer, O., Sar, S., Barnett‐Griness, O., Friedman, B., Shyriaieva, H., & Saliba, W. (2022) · Ophthalmology · doi:10.1016/j.ophtha.2022.05.015 · Cited by 43
Revolutionizing Nanovaccines: A New Era of Immunization
Saleh, M. A., El-Moghazy, A. Y., El-Gohary, A. H., Saber, W. I. A., & Helmy, Y. A. (2025) · Vaccines · doi:10.3390/vaccines13020126 · Cited by 55
“By mimicking the structure of native viruses, VLPs can induce strong immune responses, making them a versatile platform for vaccine development [261–264].”
Distinct Characteristics of COVID-19 Infection in Children
Han, X., Li, X., Xiao, Y., Yang, R., Wang, Y., & Wei, X. (2021) · Frontiers in Pediatrics · doi:10.3389/fped.2021.619738 · Cited by 44
Brain Imaging Changes in Patients Recovered From COVID-19: A Narrative Review
Huang, Y., Ling, Q., Manyande, A., Wu, D., & Xiang, B. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.855868 · Cited by 52
Rzymski, P., Pazgan−Simon, M., Simon, K. A., Łapiński, T. W., Zarębska‐Michaluk, D., Szczepańska, B., Chojnicki, M., Mozer‐Lisewska, I., & Flisiak, R. (2021) · Vaccines · doi:10.3390/vaccines9070781 · Cited by 43
Chen, Y., Lin, Y., Chang, Y., Chou, W., & Yen, C. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18137042 · Cited by 51
Tailoring biomaterials for vaccine delivery
Zhuo, Y., Zeng, H., Su, C., Lv, Q., Cheng, T., & Lei, L. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02758-0 · Cited by 53
“For example, emergency marketing authorizations were granted in 2020 for Pfizer’s BNT162b2 vaccine (Comir-naty) and Moderna’s mRNA-1273 vaccine (Spikevax), both of which utilize LNPs for mRNA antigen delivery [134, 135].”
BackgroundN1-methyl-pseudouridine is incorporated with higher fidelity than pseudouridine in synthetic RNAs
Chen, T.-H., Potapov, V., Dai, N., Ong, J. L., & Roy, B. (2022) · Scientific Reports · doi:10.1038/s41598-022-17249-1 · Cited by 49
Khehra, N., Padda, I., Jaferi, U., Atwal, H., Narain, S., & Parmar, M. S. (2021) · AAPS PharmSciTech · doi:10.1208/s12249-021-02058-y · Cited by 43
Kapoor, K. S., Harris, K., Arian, K. A., Ma, L., Zancanela, B. S., Church, K. A., McAndrews, K. M., & Kalluri, R. (2024) · Bioactive Materials · doi:10.1016/j.bioactmat.2024.08.002 · Cited by 59
COVID-19 mRNA Vaccination Generates Greater Immunoglobulin G Levels in Women Compared to Men
Demonbreun, A. R., Sancilio, A., Velez, M. E., Ryan, D. T., Pesce, L. L., Saber, R., Vaught, L. A., Reiser, N. L., Hsieh, R. R., D’Aquila, R. T., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab314 · Cited by 47
D’Offizi, G., Agrati, C., Comandini, U. V., Castilletti, C., Puro, V., Piccolo, P., Montalbano, M., Meschi, S., Tartaglia, E., Sorace, C., et al. (2021) · Liver International · doi:10.1111/liv.15089 · Cited by 46
Lasagna, A., Agustoni, F., Percivalle, E., Borgetto, S., Paulet, A., Comolli, G., Sarasini, A., Bergami, F., Sammartino, J. C., Ferrari, A., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100272 · Cited by 40
“This vaccine showed a 95% protection against SARS-CoV-2 infection in a phase II/III trial.(1) However, data on the immune response elicited by the vaccine are limited to a low number of subjects analyzed.”
Deaths associated with newly launched SARS-CoV-2 vaccination (Comirnaty®)
Edler, C., Klein, A., Schröder, A. S., Sperhake, J., & Ondruschka, B. (2021) · Legal Medicine · doi:10.1016/j.legalmed.2021.101895 · Cited by 51
Agent-based modelling of reactive vaccination of workplaces and schools against COVID-19
Faucher, B., Assab, R., Roux, J., Lévy-Bruhl, D., Kiem, C. T., Cauchemez, S., Zanetti, L. C. D. S., Colizza, V., Boëlle, P., & Poletto, C. (2022) · Nature Communications · doi:10.1038/s41467-022-29015-y · Cited by 50
Effects of PEG antibodies on in vivo performance of LNP-mRNA vaccines
Yang, M. J., Zhang, Z., Jin, P., Jiang, K., Xu, Y., Pan, F., Tian, K., Yuan, Z., Liu, X., Fu, J., et al. (2023) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2023.123695 · Cited by 46
Short-term antibody response after 1 dose of BNT162b2 vaccine in patients receiving hemodialysis
Goupil, R., Benlarbi, M., Beaubien‐Souligny, W., Nadeau‐Fredette, A., Chatterjee, D., Goyette, G., Gunaratnam, L., Lamarche, C., Tom, A., Finzi, A., et al. (2021) · Canadian Medical Association Journal · doi:10.1503/cmaj.210673 · Cited by 41
Malipiero, G., Moratto, A., Infantino, M. G., D’Agaro, P., Piscianz, E., Manfredi, M., Grossi, V., Benvenuti, E., Bulgaresi, M., Benucci, M., et al. (2021) · Immunologic Research · doi:10.1007/s12026-021-09226-z · Cited by 48
Peculiarities of the T Cell Immune Response in COVID-19
Kudlay, D. A., Кофиади, И. А., & Khaitov, M. R. (2022) · Vaccines · doi:10.3390/vaccines10020242 · Cited by 50
Bonnet, B., Chabrolles, H., Archimbaud, C., Brebion, A., Cosme, J., Dutheil, F., Lambert, C., Junda, M., Mirand, A., Ollier, A., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.842912 · Cited by 49
The effect of SARS-CoV-2 D614G mutation on BNT162b2 vaccine-elicited neutralization
Zou, J., Xie, X., Fontes-Garfias, C. R., Swanson, K. A., Kanevsky, I., Tompkins, K., Cutler, M., Cooper, D., Dormitzer, P. R., & Shi, P.-Y. (2021) · npj Vaccines · doi:10.1038/s41541-021-00313-8 · Cited by 42
Self-citationGavriatopoulou, M., Terpos, E., Ntanasis‐Stathopoulos, I., Briasoulis, Α., Gumeni, S., Malandrakis, P., Fotiou, D., Migkou, M., Theodorakakou, F., Eleutherakis‐Papaiakovou, E., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021005444 · Cited by 43
Hanson, C., Luedtke, S., Spicer, N., Sörensen, J. S., Mayhew, S., & Mounier‐Jack, S. (2021) · BMJ Global Health · doi:10.1136/bmjgh-2021-006691 · Cited by 73
Immunologic response of mRNA SARS-CoV-2 vaccination in adolescent kidney transplant recipients
Crane, C. R., Phebus, E., & Ingulli, E. G. (2021) · Pediatric Nephrology · doi:10.1007/s00467-021-05256-9 · Cited by 43
Postvaccination SARS‐CoV‐2 infection among healthcare workers: A systematic review and meta‐analysis
Chandan, S., Khan, S. R., Deliwala, S., Mohan, B., Ramai, D., Chandan, O. C., & Facciorusso, A. (2021) · medRxiv · doi:10.1002/jmv.27457 · Cited by 28
Butler, M., Coebergh, J. A., Safavi, F., Carson, A. J., Hallett, M., Michael, B. D., Pollak, T. A., Solomon, T., Stone, J., Nicholson, T. R., et al. (2021) · Journal of Neuropsychiatry · doi:10.1176/appi.neuropsych.21050116 · Cited by 42
RBD-specific antibody responses after two doses of BBIBP-CorV (Sinopharm, Beijing CNBG) vaccine
Ferenci, T., & Sarkadi, B. (2022) · BMC Infectious Diseases · doi:10.1186/s12879-022-07069-z · Cited by 45
“2% of the subjects was above 55 years of age [20] and 20.”
BackgroundResultAbdel‐Moneim, A., Radwan, M. A., & Yousef, A. I. (2022) · Current Medical Research and Opinion · doi:10.1080/03007995.2022.2078081 · Cited by 55
Transfection Potency of Lipid Nanoparticles Containing mRNA Depends on Relative Loading Levels
Liao, S., Wang, S., Wadhwa, A., Birkenshaw, A., Fox, K., Cheng, M. H. Y., Casmil, I. C., Magaña, A. A., Bathula, N. V., Ho, C.-H., et al. (2024) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.4c20077 · Cited by 50
Quer, G., Gadaleta, M., Radin, J. M., Andersen, K. G., Baca-Motes, K., Ramos, E., Topol, E. J., & Steinhubl, S. R. (2022) · npj Digital Medicine · doi:10.1038/s41746-022-00591-z · Cited by 43
Overcoming delivery barriers in immunotherapy for glioblastoma
Rui, Y., & Green, J. J. (2021) · Drug Delivery and Translational Research · doi:10.1007/s13346-021-01008-2 · Cited by 47
“The recent successful use of lipid NPs to deliver mRNA in COVID-19 vaccines [115] demonstrated the safety and efficacy of using biomaterials to stimulate the immune system.”
BackgroundSARS-CoV-2 mRNA vaccines decouple anti-viral immunity from humoral autoimmunity
Jaycox, J. R., Lucas, C. G. D. O., Yildirim, I. B., Dai, Y., Wang, E. Y., Monteiro, V. S., Lord, S. M., Carlin, J. S., Kita, M., Buckner, J. H., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36686-8 · Cited by 48
Loh, J. S., Tan, L., Lee, W.-L., Ming, L. C., How, C. W., Foo, J. B., Kifli, N., Goh, B. H., & Ong, Y. S. (2021) · Cancers · doi:10.3390/cancers13215346 · Cited by 47
“Interestingly, nanotechnology has also been employed in the development of the BioNTech/Pfizer (BNT162b2) and Moderna (mRNA-1273) COVID-19 mRNA vaccines, which encapsulated the mRNA vaccine within lipid nanoparticles [54,55].”
BackgroundMethodHuang, X., Yan, Y., Su, B., Xiao, D., Yu, M., Jin, X., Duan, J., Zhang, X., Zheng, S., Fang, Y., et al. (2021) · Viruses · doi:10.3390/v14020277 · Cited by 42
Protein-based nanoparticles for therapeutic nucleic acid delivery
Eweje, F., Walsh, M. L., Ahmad, K., Ibrahim, V., Alrefai, A., Chen, J., & Chaikof, E. L. (2024) · Biomaterials · doi:10.1016/j.biomaterials.2023.122464 · Cited by 47
Factors affecting nurses' intention to accept the COVID‐19 vaccine: A cross‐sectional study
Rabi, R., Maraqa, B. N., Nazzal, Z. A. S., & Zink, T. (2021) · Public Health Nursing · doi:10.1111/phn.12907 · Cited by 49
“Currently, sufficient information about vaccines is available (Polack et al., 2020; Voysey et al., 2021).”
The Impact of the COVID-19 Vaccine Distribution on Mental Health Outcomes
Agrawal, V., Cantor, J., Sood, N., & Whaley, C. (2021) · National Bureau of Economic Research · doi:10.3386/w29593 · Cited by 45
COVID-19 Vaccination in Korea: Past, Present, and the Way Forward
Nham, E., Song, J. Y., Noh, J. Y., Cheong, H. J., & Kim, W. J. (2022) · Journal of Korean Medical Science · doi:10.3346/jkms.2022.37.e351 · Cited by 45
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.